XIENCE 90/28: Assessment of three-month and one-month DAPT after everolimus-eluting stents in high-bleeding risk patients
Reported from the TCT Congress 2020
At TCT Connect 2020, Roxana Mehran and Marco Valgimigli presented the results of the XIENCE 90/28 trial. Watch this interview of Roxana Mehran by Francesco Costa.
The results showed that aspirin alone after 1 or 3 months was noninferior to historical controls, with significantly less major bleeding. Francesco Costa and Roxana Mehran discuss the key findings of the XIENCE 90/28 trial.
No comments yet!